Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy


This study will look at whether an investigational drug, called Ampreloxetine, works and how safe it is when taken over several months to treat symptomatic Neurogenic orthostatic hypotension in people with multiple system atrophy (MSA). It will also look at the effects of Ampreloxetine on general well-being and if it can improve symptoms of Neurogenic orthostatic hypotension.


Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 30 to 110

Inclusion criteria:

• Are at least 30 years of age
• Have symptoms related to Neurogenic orthostatic hypotension
• Have MSA


Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

Rasha Hamzeh

Principal investigator:

Satish Raj

Clinical trial: